BiotechTubeBiotechTube
Home/Pipeline/KRP-203 (Amiselimod)

KRP-203 (Amiselimod)

Ulcerative Colitis

Phase IIActive

Key Facts

Indication
Ulcerative Colitis
Phase
Phase II
Status
Active
Company
Kissei Pharmaceutical

About Kissei Pharmaceutical

Kissei Pharmaceutical is a mid-sized, research-driven Japanese pharmaceutical company with a history spanning over 70 years. Its strategic focus lies in developing and marketing novel drugs for urological, nephrological, and metabolic disorders, while also engaging in licensing and collaborative partnerships to expand its portfolio. The company leverages its expertise in drug discovery and development to address unmet medical needs, with a commercial presence in Japan and through international partnerships. Its financial stability is supported by marketed products and a pipeline of clinical-stage candidates.

View full company profile

Therapeutic Areas

UrologyNephrologyMetabolic DiseasesGastroenterologyPain

Other Ulcerative Colitis Drugs

DrugCompanyPhase
MirikizumabEli LillyPhase 3
FilgotinibGilead SciencesPhase 3
Obefazimod (ABX464)AbivaxPhase 3
Icotrokinra (JNJ-2113)Protagonist TherapeuticsPhase 3
DE-130 (Etrasimod)Rohto PharmaceuticalPhase 3
DE-122 (Carotegrast methyl)Rohto PharmaceuticalPhase 3
Methylene Blue MMX®Cosmo PharmaceuticalsPreclinical
EVO301EvommunePhase 1
Pentasa (Mesalazine)Zeria PharmaceuticalApproved/Commercial
SER-301Seres TherapeuticsPhase 1b
SER-287Seres TherapeuticsPhase 2b
IMP731ImmutepPhase 2